This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
4.MJ Sweeting , The burden of hepatitis C in England. Journal of Viral Hepatitis 2007; 14: 570–576.
5.JG McHutchison , Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 1998; 339: 1485–1492.
6.T Poynard , Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–1432.
7.MP Manns , Peg-interferon alfa-2b plus ribavirin compared with inteferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965.
8.MW Fried , Peg-interferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal Medicine 2002; 347: 975–982.
12.G Saracco , A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36: 959–966.
13.RP Myers , T Poynard . Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD003617. doi:10.1002/14651858.CD003617.
14.SJ Cheng , Interferon and Ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231–240.
Is an ‘a la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
2000; 31: 211–218.
16.TL Wright . Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185–S194.
17.BL Bressler , High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639–644.
Treatment of chronic hepatitis C with peg-interferon alfa 2a (40 kD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology
2003; 38: 246A.
19.HE Harris , The HCV National Register: towards informing the natural history of hepatitis C infection in the UK. Journal of Viral Hepatitis 2000; 7: 420–427.
21.E Jaeckel , Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine 2001; 345: 1452–1457.
22.MJ Sweeting , Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. Journal of Clinical Epidemiology 2006; 59: 144–152.
23.E Kenny-Walsh . Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. New England Journal of Medicine 1999; 340: 1228–1233.
Long-term persistence of hepatitis C virus antibodies in a single source outbreak. Journal of Hepatology
1991; 13: 323–327.
26.ML Thoman . The pattern of T lymphocyte differentiation is altered during thymic involution. Mechanisms of Ageing and Development 1995; 82: 155–170.
28.Q Ouyang , Reduced IFN-gamma production in elderly people following in vitro stimulation with influenza vaccine and endotoxin. Mechanisms of Ageing and Development 2000; 121: 131–137.
29.M Hoare , CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. Journal of Hepatology 2010; 53: 252–260.
31.S Kleinman , Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004; 44: 386–390.
Peg interferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. A randomised study of treatment duration and ribavirin dose. Annals of Internal Medicine
2004; 140: 346–355.
Impact of Interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology
2000; 32: 1131–1137.
34.G Antonucci , The Effect of age on response to therapy with pegylated alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 years. American Journal of Gastroenterology 2007; 102: 1383–1391.
Efficacy of ribavirin plus interferon- alpha in patients aged ⩾60 years with chronic hepatitis C. Journal of Gastroenterology and Hepatology
2007; 22: 989–995.
38.Y Iwasaki , Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54–63.